-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The state vigorously develops the cause of traditional Chinese medicine, adheres to the equal emphasis on traditional Chinese and Western medicine, and combines inheritance and innovation
.
On December 27, affected by the news that the state will vigorously support and promote the development of traditional Chinese medicine, the A-share traditional Chinese medicine sector strengthened again after the opening
.
Among them, Hongri Pharmaceutical rose by about 15%, Longjin Pharmaceutical had a daily limit of 4 consecutive boards, Dali Pharmaceutical, Qiqi Pharmaceutical had a daily limit, Teyi Pharmaceutical, Taiji Group, and other stocks rose
.
On December 27, Hongri Pharmaceutical rose rapidly in the intraday market.
As of 9:30, it reported 5.
6 yuan, with a turnover of 276 million yuan and a turnover rate of 1.
87%
.
The main business of Hongri Pharmaceutical Company is medicine, medical device products, raw and auxiliary materials.
According to the third quarterly report of 2021, the company achieved operating income of 5.
486 billion yuan, a year-on-year increase of 16.
52%; net profit was 637 million yuan, a year-on-year increase of 6.
34%
.
It is reported that on the basis of guaranteeing the "authentic efficacy", Red Sun Pharmaceutical has solved the problem in the production process of traditional Chinese medicine due to the origin of the single traditional Chinese medicine by making the single traditional Chinese medicine into the dosage form of "quantifiable" formula granules.
, the problems of "difference in drug efficacy" caused by artificial preparation, and provide a basis for the refined preparation of traditional Chinese medicine
.
According to Red Sun Pharmaceutical's statement on the investor interaction platform on December 20, the company has 5 1.
1 new drug projects in its research projects, 11 projects have been applied for CDE pending review, and 2 are in the clinical research stage
.
Longjin Pharmaceutical opened the market this morning, and the concept of traditional Chinese medicine became stronger again.
Longjin Pharmaceutical took over the rising banner and realized the four-connected board
.
As of the close at noon, the stock reported 11.
02 yuan per share, with a turnover of 137 million yuan.
The stock has risen by more than 50% in the past week
.
On the news, the inter-provincial alliance of 19 provinces led by Hubei carried out the centralized procurement of Chinese patent medicines, and the results of the proposed selection were announced recently.
.
According to December 27, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, indicating that the company's breviscapine for injection plans to be selected in the provincial alliance of selected patent medicines for centralized procurement with volume.
The results and selected price of this centralized procurement are still certain.
The relevant procurement contracts for the products to be selected have not been signed, the agreed procurement volume has not been clarified, and the subsequent events and the degree of impact on the company are still uncertain
.
Dali Pharmaceutical On December 27, Dali Pharmaceutical opened at 8.
2 yuan.
As of 09:35, the stock rose 9.
95% to 8.
95 yuan, closing the price limit
.
It is reported that Dali Pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections.
The main products are "Zhongjing Brand" Xingnaojing Injection and Shenmai Injection
.
The company stated that it will continue to base itself on the main business of medicine, extend and expand the industrial chain around the main business, actively seek horizontal or vertical cooperation opportunities, and achieve the company's goal of sustainable development
.
Data shows that as of September 30, 2021, Dali Pharmaceutical’s operating income was 129.
14 million yuan, the net profit attributable to shareholders of the parent company was -5.
953514 million yuan, a year-on-year decrease of 223.
1292%, and the basic earnings per share was -0.
0271 yuan
.
Miracle Pharmaceutical On December 27, Miracle Pharmaceutical opened at 5.
59 yuan.
As of 09:40, the stock rose 10.
02% to 6.
15 yuan, closing the upper limit
.
Miracle Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceuticals
.
Its existing planting and breeding bases for Chinese medicinal materials such as Polygonum multiflorum and Wushao snake, with a total area of more than 200 mu, guarantee the supply of some raw materials of the company to a certain extent
.
According to the data, as of September 30, 2021, Magic Pharma’s operating income was 1.
70309 billion yuan, and the net profit attributable to shareholders of the parent company was 53.
024372 million yuan, a year-on-year decrease of -0.
0%, and the basic earnings per share was 0.
1 yuan.
.
Teyi Pharmaceutical opened at 16.
57 yuan on December 27, and as of 10:35, the stock rose 10.
01% to 17.
69 yuan, closing the price limit
.
Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical preparations
.
As of September 30, 2021, the operating income of Teyi Pharmaceutical was 525.
47 million yuan, and the net profit attributable to shareholders of the parent company was 102.
87 million yuan, a year-on-year increase of 257.
54%
.
Recently, Teyi Pharmaceutical stated in the institutional survey that at present, there is a special production workshop for Zhikebao tablets, and the current production capacity is 1 billion tablets (about 40 million boxes).
Later, according to market needs, production equipment can be added to existing sites.
, the production capacity can reach 2.
4 billion pieces (about 100 million boxes), and it is estimated that in 5-8 years, the annual sales volume of Zhikebao tablets will reach 2.
4 billion pieces
.
Tai Chi Group On December 27, Tai Chi Group opened at 20.
11 yuan.
As of 11:05, the stock rose 10.
03% to 21.
95 yuan, closing the price limit
.
Tai Chi Group is mainly engaged in the import and export business of Chinese patent medicine, western medicine, health care products, medical packaging products, medical equipment production and sales, raw materials, and medicinal packaging of Chinese herbal medicines
.
As of September 30, 2021, Taiji Group's operating income was 9.
57006 billion yuan, and the net profit attributable to shareholders of the parent company was 248.
03 million yuan, a year-on-year increase of 1425.
54%
.
It is reported that Huoxiang Zhengqi Oral Liquid is the backbone of Taiji Group.
Due to the continuous increase in the cost of main raw materials, auxiliary materials and energy, in order to alleviate the pressure on the company's rising costs and promote the sustainable development of the market, it is reported that the company has recently begun to take Huoxiang Zhengqi Oral Liquid.
The ex-factory price of the liquid is adjusted, with an average increase of 12%
.
.
On December 27, affected by the news that the state will vigorously support and promote the development of traditional Chinese medicine, the A-share traditional Chinese medicine sector strengthened again after the opening
.
Among them, Hongri Pharmaceutical rose by about 15%, Longjin Pharmaceutical had a daily limit of 4 consecutive boards, Dali Pharmaceutical, Qiqi Pharmaceutical had a daily limit, Teyi Pharmaceutical, Taiji Group, and other stocks rose
.
On December 27, Hongri Pharmaceutical rose rapidly in the intraday market.
As of 9:30, it reported 5.
6 yuan, with a turnover of 276 million yuan and a turnover rate of 1.
87%
.
The main business of Hongri Pharmaceutical Company is medicine, medical device products, raw and auxiliary materials.
According to the third quarterly report of 2021, the company achieved operating income of 5.
486 billion yuan, a year-on-year increase of 16.
52%; net profit was 637 million yuan, a year-on-year increase of 6.
34%
.
It is reported that on the basis of guaranteeing the "authentic efficacy", Red Sun Pharmaceutical has solved the problem in the production process of traditional Chinese medicine due to the origin of the single traditional Chinese medicine by making the single traditional Chinese medicine into the dosage form of "quantifiable" formula granules.
, the problems of "difference in drug efficacy" caused by artificial preparation, and provide a basis for the refined preparation of traditional Chinese medicine
.
According to Red Sun Pharmaceutical's statement on the investor interaction platform on December 20, the company has 5 1.
1 new drug projects in its research projects, 11 projects have been applied for CDE pending review, and 2 are in the clinical research stage
.
Longjin Pharmaceutical opened the market this morning, and the concept of traditional Chinese medicine became stronger again.
Longjin Pharmaceutical took over the rising banner and realized the four-connected board
.
As of the close at noon, the stock reported 11.
02 yuan per share, with a turnover of 137 million yuan.
The stock has risen by more than 50% in the past week
.
On the news, the inter-provincial alliance of 19 provinces led by Hubei carried out the centralized procurement of Chinese patent medicines, and the results of the proposed selection were announced recently.
.
According to December 27, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, indicating that the company's breviscapine for injection plans to be selected in the provincial alliance of selected patent medicines for centralized procurement with volume.
The results and selected price of this centralized procurement are still certain.
The relevant procurement contracts for the products to be selected have not been signed, the agreed procurement volume has not been clarified, and the subsequent events and the degree of impact on the company are still uncertain
.
Dali Pharmaceutical On December 27, Dali Pharmaceutical opened at 8.
2 yuan.
As of 09:35, the stock rose 9.
95% to 8.
95 yuan, closing the price limit
.
It is reported that Dali Pharmaceutical is mainly engaged in the production and sales of Chinese and Western medicine injections.
The main products are "Zhongjing Brand" Xingnaojing Injection and Shenmai Injection
.
The company stated that it will continue to base itself on the main business of medicine, extend and expand the industrial chain around the main business, actively seek horizontal or vertical cooperation opportunities, and achieve the company's goal of sustainable development
.
Data shows that as of September 30, 2021, Dali Pharmaceutical’s operating income was 129.
14 million yuan, the net profit attributable to shareholders of the parent company was -5.
953514 million yuan, a year-on-year decrease of 223.
1292%, and the basic earnings per share was -0.
0271 yuan
.
Miracle Pharmaceutical On December 27, Miracle Pharmaceutical opened at 5.
59 yuan.
As of 09:40, the stock rose 10.
02% to 6.
15 yuan, closing the upper limit
.
Miracle Pharmaceutical is mainly engaged in the research and development, production and sales of pharmaceuticals
.
Its existing planting and breeding bases for Chinese medicinal materials such as Polygonum multiflorum and Wushao snake, with a total area of more than 200 mu, guarantee the supply of some raw materials of the company to a certain extent
.
According to the data, as of September 30, 2021, Magic Pharma’s operating income was 1.
70309 billion yuan, and the net profit attributable to shareholders of the parent company was 53.
024372 million yuan, a year-on-year decrease of -0.
0%, and the basic earnings per share was 0.
1 yuan.
.
Teyi Pharmaceutical opened at 16.
57 yuan on December 27, and as of 10:35, the stock rose 10.
01% to 17.
69 yuan, closing the price limit
.
Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical preparations
.
As of September 30, 2021, the operating income of Teyi Pharmaceutical was 525.
47 million yuan, and the net profit attributable to shareholders of the parent company was 102.
87 million yuan, a year-on-year increase of 257.
54%
.
Recently, Teyi Pharmaceutical stated in the institutional survey that at present, there is a special production workshop for Zhikebao tablets, and the current production capacity is 1 billion tablets (about 40 million boxes).
Later, according to market needs, production equipment can be added to existing sites.
, the production capacity can reach 2.
4 billion pieces (about 100 million boxes), and it is estimated that in 5-8 years, the annual sales volume of Zhikebao tablets will reach 2.
4 billion pieces
.
Tai Chi Group On December 27, Tai Chi Group opened at 20.
11 yuan.
As of 11:05, the stock rose 10.
03% to 21.
95 yuan, closing the price limit
.
Tai Chi Group is mainly engaged in the import and export business of Chinese patent medicine, western medicine, health care products, medical packaging products, medical equipment production and sales, raw materials, and medicinal packaging of Chinese herbal medicines
.
As of September 30, 2021, Taiji Group's operating income was 9.
57006 billion yuan, and the net profit attributable to shareholders of the parent company was 248.
03 million yuan, a year-on-year increase of 1425.
54%
.
It is reported that Huoxiang Zhengqi Oral Liquid is the backbone of Taiji Group.
Due to the continuous increase in the cost of main raw materials, auxiliary materials and energy, in order to alleviate the pressure on the company's rising costs and promote the sustainable development of the market, it is reported that the company has recently begun to take Huoxiang Zhengqi Oral Liquid.
The ex-factory price of the liquid is adjusted, with an average increase of 12%
.
